AC Immune SA (ACIU)

NGM – Real Time Price. Currency in USD

2.56

+0.11 (4.49%)

At close: Jun 26, 2026, 4:00 PM EDT

2.58

+0.02 (0.78%)

After-hours: Jun 26, 2026, 4:27 PM EDT

11.06.2026

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years Final data from Part 1 of VacSYn trial expected in H2 2026 Lausanne, Switzerland, June 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will receive a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, AC Immune's anti-alpha-synuclein (a-syn) active immunotherapy, in early Parkinson's disease (PD).

03.06.2026

AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

22.05.2026

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS) Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD) Underlines potential for precision medicine enabling early diagnosis and intervention in multiple neurodegenerative diseases Lausanne, Switzerland, May 22, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography (PET) tracer ACI-19626 showing increased uptake in the brains of patients with amyotrophic lateral sclerosis (ALS). The results presented at the 2026 TDP43 Summit in Madison, Wisconsin, demonstrate that PET scans with ACI-19626 showed tracer uptake significantly higher in key regions of the brain in patients with ALS compared to healthy controls.

15.05.2026

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

14.05.2026

AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

12.05.2026

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appointed interim CEO Dr Pfeifer to serve as an Advisor and Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board Company well-positioned to drive short- and long-term value creation via its wholly-owned pipeline and strategic partnerships Robust balance sheet following recently achieved milestones, with multiple further near-term value-inflection milestones Lausanne, Switzerland, 12 May 2026 -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces that Dr Andrea Pfeifer has decided to retire from her role as Chief Executive Officer (CEO) of AC Immune at the upcoming Annual General Meeting (AGM) to spend more time with her family. AC Immune's Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.

30.04.2026

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

AC Immune (ACIU) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.

Videos

No Data

There is no data to display

Press releases

11.06.2026

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

22.05.2026

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

15.05.2026

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

12.05.2026

AC Immune SA (ACIU)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AC Immune SA (ACIU)

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

Videos

No Data

Press releases

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

Videos

No Data

Press releases

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

Search stocks

AC Immune SA (ACIU)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AC Immune SA (ACIU)

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

Videos

No Data

Press releases

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune (ACIU) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates

Videos

No Data

Press releases

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM